Merck's Keytruda helps lung cancer patients live longer in trial
Monday, 9 April 2018 () (Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market.
Apr.16 -- Merck & Co. is cementing its lead in lung cancer therapy, fending off rival Bristol-Myers Squibb Co. after new data that could reshape treatment of the deadly disease. Bloomberg's Taylor Riggs reports on "Bloomberg Markets: Balance of Power."
LONDON (Reuters) - A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed... Reuters India - HealthAlso reported by •DNA
New Delhi, Apr 19 (ANI): A new protein has been found that is associated with breast cancer patients' survival. According to a study conducted by the UT Southwestern Medical Center, this protein.. Source: Health Tips -
According to upi.com, "Researchers have devised a new gene mapping technique that allows medical providers to determine the chemotherapy with the fewest side effects and best success for individual.. Source: Wochit News -
Doctors have a powerful new approach to fighting lung cancer, the leading cause of cancer deaths. Two studies released Monday show drugs that boosted patients' immune systems can dramatically improve.. Source: CBSN -
According to a new report, lung cancer patients live longer while on immune therapy.
Using a combination of immunotherapy drugs, doctors found that pre-treating lung cancer patients before surgery can.. Source: Wochit -
According to Business Insider, "New cancer treatments that harness the body's immune system are ready to go mainstream... cancer drugmakers showed that the use of immunotherapy in combination with.. Source: Wochit -